Advicenne

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated Advicenne logo

E_DEPRECATED Error in file �functions_general.php� at line 186: Function utf8_encode() is deprecated

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.

Keywords:

Date	News
2018-05-25	Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress (PDF)
2018-05-15	Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe (PDF)
2018-05-04	Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria (PDF)
2018-04-30	Advicenne publishes its annual financial report (PDF)
2018-04-10	Advicenne 2017 Financial Results and Operational Perspectives for 2018 (PDF)
2018-02-12	Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017 (PDF)
2018-01-24	Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs (PDF)
2018-01-05	Partial exercise of over – allotment option (PDF)
2017-12-05	Success of the IPO
2017-11-06	ADV7103: 6-month data presented at ASN (PDF)

Date

News

2018-05-25

Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress (PDF)

2018-05-15

Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe (PDF)

2018-05-04

Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria (PDF)

2018-04-30

Advicenne publishes its annual financial report (PDF)

2018-04-10

Advicenne 2017 Financial Results and Operational Perspectives for 2018 (PDF)